# Amgen

Source: https://onco.cc/companies/amgen/  
OnCo record `amgen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amgen invented the BiTE T-cell engager format and the first KRAS inhibitor.

## Summary

Amgen, based in Thousand Oaks, California, and listed as AMGN, invented the BiTE T-cell engager format and made the first KRAS inhibitor. Its oncology portfolio includes blinatumomab, tarlatamab, the first solid-tumour T-cell engager to show an overall survival benefit, sotorasib, bemarituzumab against FGFR2b, xaluritamig, a STEAP1 by CD3 engager, the oncolytic virus Imlygic, and supportive care products including denosumab and darbepoetin alfa. OnCo links it to the AALL1731 and E1910 blinatumomab papers, to CodeBreaK 200 and CodeBreaK 300 for sotorasib, to DeLLphi-301 for tarlatamab, to PRMT5 in MTAP-deleted cancers, to the KIF18A idea, and to the bottleneck of wrong doses. Whether T-cell engagers can work in common solid tumours beyond small-cell lung cancer is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: BioVex Limited; BioVex
- HQ: Thousand Oaks, CA
- Type: pharma
- Website: https://www.amgen.com
- Ticker: AMGN

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Amgen
- Official website: https://www.amgen.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Anvumetostat](https://onco.cc/drugs/anvumetostat/), [Bemarituzumab](https://onco.cc/drugs/bemarituzumab/), [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Cinacalcet](https://onco.cc/drugs/cinacalcet/), [Darbepoetin alfa](https://onco.cc/drugs/darbepoetin-alfa/), [Denosumab](https://onco.cc/drugs/denosumab/), [Epoetin alfa](https://onco.cc/drugs/epoetin-alfa/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/), [Romiplostim](https://onco.cc/drugs/romiplostim/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/), [Xaluritamig](https://onco.cc/drugs/xaluritamig/)
- trials: [A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)](https://onco.cc/trials/nct06593522/), [A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)](https://onco.cc/trials/nct05060016/), [A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC](https://onco.cc/trials/nct06745323/), [A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation](https://onco.cc/trials/nct07172919/), [A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small](https://onco.cc/trials/nct07005128/), [A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi](https://onco.cc/trials/nct05920356/), [A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)](https://onco.cc/trials/nct05094336/), [A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL](https://onco.cc/trials/nct04521231/), [A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct07134088/), [A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ](https://onco.cc/trials/nct07213674/), [A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06311721/), [A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct06054555/), [A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2](https://onco.cc/trials/nct07203053/), [ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer](https://onco.cc/trials/nct00261313/), [An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma](https://onco.cc/trials/nct01368276/), [CodeBreaK 100 (pancreatic cancer cohort)](https://onco.cc/trials/codebreak-100/), [CodeBreaK 200](https://onco.cc/trials/codebreak-200/), [CodeBreaK 300](https://onco.cc/trials/codebreak-300/), [DeLLphi-304](https://onco.cc/trials/dellphi-304/), [DeLLphi-305](https://onco.cc/trials/dellphi-305/), [Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma](https://onco.cc/trials/nct00769704/), [FORTITUDE-101](https://onco.cc/trials/fortitude-101/), [Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma](https://onco.cc/trials/nct02263508/), [Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)](https://onco.cc/trials/nct06430866/), [Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)](https://onco.cc/trials/nct07778316/), [PRIME](https://onco.cc/trials/prime/), [Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors](https://onco.cc/trials/nct06814496/), [Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)](https://onco.cc/trials/nct06117774/), [Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment](https://onco.cc/trials/nct06502977/), [Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri](https://onco.cc/trials/nct07016230/), [Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer](https://onco.cc/trials/nct03937154/), [Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal](https://onco.cc/trials/nct06252649/), [Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu](https://onco.cc/trials/nct03635021/), [Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer](https://onco.cc/trials/nct07637513/), [Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer](https://onco.cc/trials/nct07423585/), [TOWER](https://onco.cc/trials/tower/), [XALute](https://onco.cc/trials/xalute/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- key papers: [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug](https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/), [CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer](https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus](https://onco.cc/key-papers/paper-andtbacka-optim-talimogene-jco-2015/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/)
- technologies: [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- bottlenecks: [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- ideas: [Turn chromosomal chaos into a weakness with KIF18A inhibitors](https://onco.cc/ideas/idea-bio1-cin-vulnerability-kif18a/)
- targets: [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/)
- companies: [Amgen Ventures](https://onco.cc/companies/amgen-ventures/)

---
JSON: https://onco.cc/api/v1/entities/amgen.json